Skip to main content

Athenex, Inc.

ATNXDelisted Jul 10, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001300699

Athenex, Inc. was delisted on Jul 10, 2023; its insiders filed their last Form 4 on May 8, 2023; 30 institutions reported holding it in 13F filings for Q1 2023, worth $2.43M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Athenex, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Athenex, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Athenex, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lau Johnson Yiu NamCEO and Chairman of the Board250,397May 8, 20230
Kwan RudolfEVP, Chief Medical Officer49,816May 8, 20230
Cook Timothy DeVereSee Remarks4,140May 8, 20230
Vierling JohnDirector12,329Apr 24, 20230
Wu JinnDirector34,802Apr 24, 20230
Spiegel Robert J.Director4,592Apr 24, 20230
Fok MansonDirector110,675Apr 24, 20230
TSANG Benson Kwan HungDirector16,920Apr 24, 20230
Davis Stephanie ADirector8,015Apr 24, 20230
Annoni JoeChief Financial Officer375Feb 27, 20230
Lang DanielPres Cell Therapy, VP Corp Dev81,590Sep 19, 20220
Kanfer JordanDirector17,086Aug 30, 20220
Yordon JeffreySee Remarks245,943Aug 15, 20220
Smolinski MichaelChief Scientific Officer–Jan 10, 20220
Adams Steven J.Interim Chief Acct Officer–Aug 17, 20210
Campbell KimDirector–Aug 5, 20210
Pedder SimonSee Remarks–Aug 5, 20210
Zuo William WeiPresident, China Division–Aug 5, 20210
Bair Teresa BrophyGeneral Counsel, SVP Admin.–Aug 5, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 30, 2022 (view filing)6:20 PM ETAug 228 daysLateWu JinnDirectorPPurchase+10.0K$0.4221+$4.22K+2.1%484.8K after
Aug 19, 2022 (view filing)4:25 PM ETAug 19Same dayLau Johnson Yiu NamCEO and Chairman of the BoardPPurchase+20.0K$0.4549+$9.10K+0.6%3.55M after
Nov 22, 2021 (view filing)Nov 22Same dayLau Johnson Yiu NamCEO and Chairman of the BoardPPurchase+3.00K$1.84+$5.52K+0.1%3.27M after
Nov 18, 2021 (view filing)Nov 18Same dayLau Johnson Yiu NamCEO and Chairman of the BoardPPurchase+3.00K$1.87+$5.61K+0.1%3.27M after
Nov 18, 2021 (view filing)Nov 171 dayKanfer JordanDirectorPPurchase+4.95K$2.02+$10.0K+106.9%9.59K after
Nov 17, 2021 (view filing)Nov 161 dayKwan RudolfEVP, Chief Medical OfficerPPurchase+4.00K$2.05+$8.20K+2.4%173.6K after
Nov 17, 2021 (view filing)Nov 17Same dayWu JinnDirectorPPurchase+30.0K$2.03+$60.9K+7.4%433.2K after2 lots
Nov 16, 2021 (view filing)Nov 16Same dayLau Johnson Yiu NamCEO and Chairman of the BoardPPurchase+3.00K$2.06+$6.18K+0.1%3.27M after
Nov 15, 2021 (view filing)Nov 15Same dayLau Johnson Yiu NamCEO and Chairman of the BoardPPurchase+5.00K$2.12+$10.6K+0.2%3.27M after
Nov 12, 2021 (view filing)Nov 12Same dayLau Johnson Yiu NamCEO and Chairman of the BoardPPurchase+10.0K$2.07+$20.7K+0.3%3.26M after
Oct 13, 2021 (view filing)Oct 112 daysLateWu JinnDirectorPPurchase+10.0K$2.67+$26.7K+2.5%413.2K after
Sep 14, 2021 (view filing)Sep 14Same dayWu JinnDirectorPPurchase+50.0K$3.22+$161.0K+14.2%403.2K after